NIH bumps up support for neurological drug development

08/1/2013 | Genetic Engineering & Biotechnology News

The NIH will fund three new projects through its Blueprint Neurotherapeutics Network initiative, under which NIH staff form partnerships with awardee investigators. Sage Therapeutics won funding for Fragile X syndrome drugs, the Scripps Research Institute won an award for nicotine addiction treatments and the University of Utah won funding for drugs to treat age-related macular degeneration.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA